Related Experiment Video

Updated: May 31, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant

S Wu1, R K Singh

  • 1Department of Pathology and Microbiology, University of Nebraska Medical Center, 85900 Nebraska Medical Center, Omaha, NE 68198-5900, USA.

Current Molecular Medicine
|June 29, 2011
PubMed

Insights

Metastatic melanoma treatment faces challenges due to therapy resistance. Combining therapies targeting survival signals may improve outcomes for advanced melanoma patients.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Metastatic melanoma is a challenging cancer with limited treatment efficacy.
  • Therapy resistance is a primary cause of treatment failure in melanoma.
  • Melanoma cells evade chemotherapy through defective apoptosis and increased survival signals.

Purpose of the Study:

  • To review inhibitors targeting melanoma growth and survival pathways.
  • To explore the rationale for combining systemic chemotherapy with targeted therapies.
  • To discuss strategies for overcoming resistance mechanisms in advanced melanoma.

Main Methods:

  • Literature review of molecular inhibitors and combination therapy strategies.
  • Analysis of melanoma cell resistance mechanisms, including apoptotic defects and survival signaling.
  • Evaluation of potential combination regimens for advanced melanoma.

Main Results:

  • Inhibitors targeting growth/survival factors show promise for combination therapy.
  • Understanding resistance mechanisms informs the development of vertical and horizontal combination strategies.
  • Combination therapy holds potential for improving survival and quality of life.

Conclusions:

  • Combination therapy is a promising strategy to overcome treatment resistance in metastatic melanoma.
  • Targeting both apoptotic defects and survival signals is crucial for effective treatment.
  • Further research into drug interactions is needed to optimize combination regimens.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.